28
Oversold
Moving averages
SMA 200$11.12-4.50%
Company profile
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
SectorHealthcare
IndustryBiotechnology
Market cap$155.82M
P/E ratioNone
EPS$-3.55
Beta1.412
Dividend yield0.00%
52-week high$17.43
52-week low$5.06
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 44
VRTX
Vertex Pharmaceuticals Inc
RSI 41
CRSP
CRISPR Therapeutics AG
RSI 55
IOVA
Iovance Biotherapeutics Inc
RSI 76
RXRX
Recursion Pharmaceuticals Inc - Class A
RSI 62
MRNA
Moderna Inc
RSI 63
VKTX
Viking Therapeutics Inc
RSI 31
SRPT
Sarepta Therapeutics Inc
RSI 50
EDIT
Editas Medicine Inc
RSI 43
NVAX
Novavax Inc
RSI 62
RSI alerts for IMUX
Get an email the moment Immunic Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 13 September 2026 at 11:13 AM EDT